Special Emphasis Panel for Translational and Diagnostic Oncology R21 – TCO82
This study section reviews R21 applications addressing the discovery, validation and development of biomarkers for early detection, diagnosis, and prognosis of cancer. Studies on markers related to predicting treatment response and monitoring therapeutic efficacy are also considered. The development of bioassays for the discovery and testing of cancer markers may be assigned to this SEP.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Identification of biomarkers for cancer detection, differential diagnosis, prognosis, predicting response to therapy, measuring tumor burden through analysis and/or molecular profiling of DNA, RNA, and protein from tumor tissue or body fluids
- Validation of new biomarkers using animal models, human materials and clinical trials.
- Early Phase-I clinical trials where the primary goal is marker validation.
- Early detection of cancer or monitoring its progression or response to therapy using available medical imaging approaches.
- Computational modeling, biostatistical analysis and informatics that facilitate the discovery, evaluation, and use of markers.
